AVXL
(NASDAQ)
5.90
-0.0800   (-1.34%)
Pre-market: .00 -5.90 (-100.00%)
Volume (24h) Market Cap. Day Range 52w Range
883.65K 355.12M 5.71 - 6.03 2.21 - 6.31
Oct-16-20 12:54PM Anavex (AVXL) in Focus: Stock Moves 9.5% HigherZacks
Oct-15-20 07:13PM Here's Why Anavex Life Sciences Jumped Higher TodayMotley Fool
11:00AM Anavex Life Sciences Announces Positive Results from Proof of Concept controlled Phase 2 Clinical Trial Evaluating ANAVEX®2-73 (blarcamesine) in Parkinson’s Disease DementiaGlobeNewswire
Sep-10-20 11:00AM Anavex Life Sciences Announces Completion of ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialGlobeNewswire
Sep-08-20 11:00AM Anavex Life Sciences to Present at Upcoming Global Healthcare ConferencesGlobeNewswire
Sep-02-20 11:01AM We're Not Very Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn RateSimply Wall St.
Aug-19-20 11:00AM Anavex Life Sciences Announces Commitment for Financial Investment by Shake It Up Foundation for Parkinson’s Research for Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Parkinson’s DiseaseGlobeNewswire
Aug-06-20 11:00AM Anavex Life Sciences Reports Fiscal 2020 Third Quarter Financial Results And Provides Business UpdatesGlobeNewswire
Aug-05-20 08:05PM Anavex Life Sciences Receives TGA Special Access Scheme Approval for ANAVEX®2-73 (blarcamesine) for Alzheimer’s Disease PatientsGlobeNewswire
Aug-04-20 11:00AM Anavex Life Sciences to Announce Fiscal 2020 Third Quarter Financial Results on Thursday, August 6th, 2020GlobeNewswire
Jul-06-20 11:00AM Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)GlobeNewswire
Jul-01-20 11:00AM Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett SyndromeGlobeNewswire
Jun-26-20 04:00PM Here's Why Anavex Life Sciences (AVXL) is a Great Momentum Stock to BuyZacks
Jun-18-20 03:30PM Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?Zacks
Jun-16-20 11:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical TrialGlobeNewswire
Jun-15-20 04:00PM Anavex Life Sciences (AVXL) Moves to Buy: Rationale Behind the UpgradeZacks
01:07AM Should You Buy Anavex Life Sciences Corp. (AVXL)?Insider Monkey
Jun-12-20 01:45PM 3 “Strong Buy” Penny Stocks With Massive Upside AheadTipRanks
Jun-11-20 10:15PM Edited Transcript of AVXL earnings conference call or presentation 7-May-20 8:30pm GMTThomson Reuters StreetEvents
Jun-04-20 11:00AM Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s DiseaseGlobeNewswire
Jun-02-20 03:30PM Has Anavex Life Sciences (AVXL) Outpaced Other Medical Stocks This Year?Zacks
Jun-01-20 11:59AM Anavex's Shares March Higher, Can It Continue?Zacks
May-21-20 11:00AM Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)GlobeNewswire
May-14-20 02:07PM Why You Shouldn't Bet Against Anavex Life Sciences (AVXL) StockZacks
May-13-20 04:00PM Anavex Life Sciences (AVXL) Upgraded to Strong Buy: Here's WhyZacks
May-08-20 05:53PM Edited Transcript of AVXL earnings conference call or presentation 7-May-20 8:30pm GMTThomson Reuters StreetEvents
May-07-20 11:00AM Anavex Life Sciences Reports Fiscal 2020 Second Quarter Financial Results And Provides Business UpdatesGlobeNewswire
May-05-20 11:00AM Anavex Life Sciences to Announce Fiscal 2020 Second Quarter Financial Results on Thursday, May 7th, 2020GlobeNewswire
Apr-23-20 11:00AM Anavex Life Sciences Announces Publication of Clinical Data for ANAVEX®2-73 (blarcamesine) in Alzheimer’s DiseaseGlobeNewswire
Apr-14-20 03:48PM Will Anavex Life Sciences Continue to Surge Higher?Zacks
Apr-03-20 09:45PM Anavex Life Sciences (AVXL) Stock Moves -0.38%: What You Should KnowZacks
Mar-31-20 11:00AM Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19GlobeNewswire
Mar-23-20 12:00PM Anavex Life Sciences to Webcast 2020 Annual Meeting of ShareholdersGlobeNewswire
Feb-24-20 12:00PM Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS)GlobeNewswire
Feb-14-20 02:18PM Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4Zacks
Feb-13-20 05:48PM 4 Momentum Stocks To WatchBenzinga
Feb-11-20 02:22PM Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDAZacks
03:56AM Edited Transcript of AVXL earnings conference call or presentation 6-Feb-20 9:30pm GMTThomson Reuters StreetEvents
Feb-06-20 07:30PM Anavex Life Sciences Corp. to Host Earnings CallACCESSWIRE
12:00PM Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study UpdatesGlobeNewswire
Feb-04-20 12:00PM Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor ConferenceGlobeNewswire
Feb-03-20 12:00PM Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Development Program for the Treatment of Rett SyndromeGlobeNewswire
Jan-31-20 04:30PM Is Anavex Life Sciences (AVXL) Stock Outpacing Its Medical Peers This Year?Zacks
Jan-30-20 12:00PM Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020GlobeNewswire
Jan-27-20 12:00PM Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Disease Dementia (PDD) Clinical TrialGlobeNewswire
Jan-23-20 01:42PM Implied Volatility Surging for Anavex (AVXL) Stock OptionsZacks
Jan-17-20 01:16PM Arena's (ARNA) Heart Failure Candidate Gets Fast Track StatusZacks
Jan-15-20 09:34PM Alexion to Start Pivotal Study on Ultomiris for ALS in Q1Zacks
Jan-14-20 05:00PM Anavex Life Sciences (AVXL) Moves to Strong Buy: Rationale Behind the UpgradeZacks
Jan-08-20 01:53PM Amarin Posts '19 Preliminary Results, Gives 2020 Expense ViewZacks
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of Alzheimer's disease, other central nervous system diseases, pain, and various cancers. The company's lead drug candidates include ANAVEX 2-73, which has completed Phase IIa clinical trials for the treatment of Alzheimer's disease; and in preclinical clinical trials to treat Parkinson's disease, epilepsy, Rett syndrome, Angelman syndrome, multiple sclerosis, and Fragile X syndrome. Its preclinical drug candidates include ANAVEX 3-71 to treat Alzheimer's disease; ANAVEX 1-41, a sigma-1 agonist; ANAVEX 1037 for the treatment of prostate cancer; and ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the treatment of neuropathic and visceral pain. The company was founded in 2006 and is based in New York, New York.
Cap:    |  Volume (24h):